Loading...
XKRX
086900
Market cap320mUSD
Oct 08, Last price  
65,900.00KRW
1D
-2.37%
1Q
-9.35%
Jan 2017
-81.52%
IPO
-58.16%
Name

Medy Tox Inc

Chart & performance

D1W1MN
XKRX:086900 chart
P/E
25.88
P/S
1.74
EPS
2,546.08
Div yield, %
1.82%
Shrs. gr., 5y
2.61%
Rev. gr., 5y
11.92%
Revenues
247.29b
+8.17%
36,262,446,94039,141,030,12075,892,308,00088,505,437,514133,255,671,034181,239,191,116205,444,934,515205,900,276,000140,827,515,000184,869,548,000195,096,220,000221,120,683,000228,621,969,000247,290,289,000
Net income
16.59b
-2.13%
15,436,739,78014,303,536,78043,627,867,04042,292,784,52859,231,019,51570,106,132,63769,963,675,93326,205,603,000-29,576,743,00094,153,921,00037,009,995,0009,755,099,00016,954,995,00016,594,167,000
CFO
61.48b
+68.18%
14,779,384,52016,596,271,730105,379,387,53023,259,440,53653,443,912,35554,655,924,75453,462,056,56131,976,962,00027,926,686,00019,965,518,00024,135,316,00013,521,519,00036,556,164,00061,481,386,000
Dividend
Sep 29, 20251200 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Medy-Tox Inc., a biopharmaceutical company established in 2000 and headquartered in Cheongju, South Korea, develops and distributes a diverse array of medical products. Its offerings include several botulinum toxin treatments: Neuronox, a lyophilized injectable powder, which is utilized for treating foot deformities caused by spasticity in children with cerebral palsy; INNOTOX, a transparent liquid injectable solution aimed at the temporary improvement of moderate to severe glabellar wrinkles; and Coretox, another freeze-dried injectable powder, also formulated for temporarily reducing moderate to severe frown lines. The company also manufactures hyaluronic acid-based dermal fillers, such as Neuramis and Potenfill, which function as tissue-recovering biomaterials. Beyond injectables, Medy-Tox provides various medical devices, including ComfortDual and Recell Ice, designed for tissue coagulation using high-frequency current; Neurajet Plus, an assisting tool for administering other pharmaceuticals; Carewave, which employs low-intensity electromagnetic shockwaves to address erectile dysfunction; and Careveam, an ultraviolet light device for managing skin ailments. Furthermore, the company offers Neurakin cream, a topical treatment for a range of dermatological conditions including acute and chronic eczema, contact and atopic dermatitis, rosacea and perioral dermatitis, herpes zoster, and acne vulgaris. Medy-Tox's products are exported to approximately 60 countries worldwide, with key markets encompassing Japan, Thailand, and Brazil. The company is also collaborating with Dyadic International, Inc. to develop vaccines targeting COVID-19 variants.

Key people

Seong Cheol Choi
Managing Director · since 2023
Gwang Jun Yoo
Managing Director · since 2023
Tae Kim
Assistant Managing Director · since 2024
Hak Wu Kim
Head of Factory, Director · since 2025
Chantal Leblanc
Assistant Managing Director · since 2023
Wu Seon Lee
Assistant Managing Director · since 2023
Chang Hun Lee
Assistant Managing Director · since 2024
Seung Beom Park
Assistant Managing Director · since 2019
Hui Seok Joo
Vice President, Director · since 2021
Hyeon Ho Jung
Chief Executive Officer, Director
Nam Cheol Seo
Internal Auditor, Director · since 2025
Hyo Jin Shin
Director · since 2022
Do Hyeon Jung
Non-Executive Independent Director · since 2023
Jeong Mi Oh
Non-Executive Independent Director · since 2023
IPO date
Jan 16, 2009
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT